B. Braun Medical, Inc.; Withdrawal of Approval of Three New Drug Applications and One Abbreviated New Drug Application; Correction, 42098 [2017-18813]

Download as PDF 42098 Federal Register / Vol. 82, No. 171 / Wednesday, September 6, 2017 / Notices ESTIMATED ANNUALIZED BURDEN HOURS—Continued Number of respondents Number of responses per respondent Average burden per response (in hours) Total burden (in hours) Type of respondents Form name Crew Members .................................. Interview protocol ............................. 250 1 10/60 42 Total ........................................... ........................................................... ........................ ........................ ........................ 44 Leroy A. Richardson, Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2017–18814 Filed 9–5–17; 8:45 am] Development of a List of Pre-Dietary Supplement Health and Education Act Dietary Ingredients; Public Meeting; Request for Comments BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of public meeting; request for comments. ACTION: Food and Drug Administration, HHS. Notice; correction. The Food and Drug Administration (FDA) is correcting a document entitled ‘‘B. Braun Medical, Inc.; Withdrawal of Approval of Three New Drug Applications and One Abbreviated New Drug Application’’ that appeared in the Federal Register of August 3, 2017 (82 FR 36150). The document was published with the incorrect docket number. This document corrects that error. FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy, Food and Drug Administration, Bldg. 32, Rm. 3330, Silver Spring, MD 20993–0002, 301– 796–9115. SUPPLEMENTARY INFORMATION: In the Federal Register of Thursday, August 3, 2017, in FR Doc. 2017–16377, on page 36150, the following correction is made: 1. On page 36150, in the second column, in the header of the document, ‘‘Docket No. FDA–2017–N–0002’’ is corrected to read ‘‘Docket No. FDA– 2017–N–4642’’. asabaliauskas on DSKBBXCHB2PROD with NOTICES Dated: August 28, 2017. Anna K. Abram, Deputy Commissioner for Policy, Planning, Legislation, and Analysis. [FR Doc. 2017–18813 Filed 9–5–17; 8:45 am] BILLING CODE 4164–01–P VerDate Sep<11>2014 17:37 Sep 05, 2017 Jkt 241001 The Food and Drug Administration (FDA or we) is announcing the following public meeting entitled ‘‘Development of a List of Pre-DSHEA Dietary Ingredients.’’ The purpose of the meeting is to give interested stakeholders an opportunity to discuss issues related to FDA’s future development of such a list. DATES: The public meeting will be held on October 3, 2017, from 8 a.m. to 5 p.m. Submit either electronic or written comments on this public meeting by December 4, 2017. See the SUPPLEMENTARY INFORMATION section for registration date and information. ADDRESSES: The public meeting will be held at FDA’s Center for Food Safety and Applied Nutrition, Wiley Auditorium, 5001 Campus Dr., College Park, MD 20740. You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before December 4, 2017. The https://www.regulations.gov electronic filing system will accept comments until midnight Eastern Time at the end of December 4, 2017. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. SUMMARY: B. Braun Medical, Inc.; Withdrawal of Approval of Three New Drug Applications and One Abbreviated New Drug Application; Correction SUMMARY: Food and Drug Administration, HHS. [Docket No. FDA–2017–N–4642] ACTION: [Docket No. FDA–2017–N–4625] AGENCY: Food and Drug Administration AGENCY: Food and Drug Administration Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2017–N–4625 for ‘‘Development of a List of Pre-DSHEA Dietary Ingredients; Public Meeting; Request for Comments.’’ Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. • Confidential Submissions—To submit a comment with confidential E:\FR\FM\06SEN1.SGM 06SEN1

Agencies

[Federal Register Volume 82, Number 171 (Wednesday, September 6, 2017)]
[Notices]
[Page 42098]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-18813]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-4642]


B. Braun Medical, Inc.; Withdrawal of Approval of Three New Drug 
Applications and One Abbreviated New Drug Application; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a 
document entitled ``B. Braun Medical, Inc.; Withdrawal of Approval of 
Three New Drug Applications and One Abbreviated New Drug Application'' 
that appeared in the Federal Register of August 3, 2017 (82 FR 36150). 
The document was published with the incorrect docket number. This 
document corrects that error.

FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy, Food 
and Drug Administration, Bldg. 32, Rm. 3330, Silver Spring, MD 20993-
0002, 301-796-9115.

SUPPLEMENTARY INFORMATION: In the Federal Register of Thursday, August 
3, 2017, in FR Doc. 2017-16377, on page 36150, the following correction 
is made:
    1. On page 36150, in the second column, in the header of the 
document, ``Docket No. FDA-2017-N-0002'' is corrected to read ``Docket 
No. FDA-2017-N-4642''.

    Dated: August 28, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-18813 Filed 9-5-17; 8:45 am]
 BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.